Condition Results Operations Refer company Annual Report Form 10-K year ended December 31 2016 2016 Annual Report management discussion analysis financial condition results operations company The following management discussion analysis financial condition results operations company three nine months ended September 30 2017 RESULTS OF OPERATIONS Baxter income continuing operations three nine months ended September 30 2017 totaled 248 million 0.45 per diluted share 785 million 1.42 per diluted share compared 127 million 0.23 per diluted share 4.7 billion 8.56 per diluted share three nine months ended September 30 2016 Income continuing operations three nine months ended September 30 2017 included special items decreased income continuing operations 108 million 237 million respectively 0.19 0.42 per diluted share respectively discussed Income continuing operations three months ended September 30 2016 included special items reduced income continuing operations 184 million 0.33 per diluted share Special items increased income continuing operations 4 billion 7.17 per diluted share nine months ended September 30 2016 Special Items The following table provides summary company special items related impact line item company results continuing operations three nine months ended September 30 2017 2016 Three months ended September 30 Nine months ended September 30 millions 2017 2016 2017 2016 Gross Margin Intangible asset amortization expense 38 42 112 124 Business optimization items 1 12 35 42 113 Product-related items 2 21 17 12 Separation-related costs 4 1 1 1 Claris acquisition integration expenses 8 4 4 Hurricane Maria costs 10 21 21 Intangible asset impairment 3 51 Total Special Items 96 78 197 277 Impact Gross Margin Ratio 3.5 pts 3.0 pts 2.5 pts 3.7 pts Marketing Administrative Expenses Business optimization items 1 39 106 74 137 Separation-related costs 4 2 9 16 45 Claris acquisition integration expenses 8 11 16 Historical reserve adjustments 5 12 Total Special Items 52 115 94 182 Impact Marketing Administrative Expense Ratio 1.9 pts 4.5 pts 1.2 pts 2.4 pts Research Development Expenses Business optimization items 1 1 30 75 Total Special Items 1 30 75 Other Expense Income Net Loss debt extinguishment 6 48 149 Net realized gains Baxalta Retained Share transactions 7 4,391 Venezuela deconsolidation 9 33 Total Special Items 48 33 4,242 Income Tax Expense Benefit Impact special items 41 87 87 252 Total Special Items 41 87 87 252 Impact Effective Tax Rate 4.4 pts 21.3 pts 3.1 pts 21.9 pts 26 Intangible asset amortization expense identified special item facilitate evaluation current past operating performance similar management internally assesses performance Additional special items identified highly variable difficult predict size may substantially impact company reported operations period Management believes providing separate impact items company results accordance GAAP United States may provide complete understanding company operations facilitate fuller analysis company results operations particularly evaluating performance one period another This information considered addition substitute information prepared accordance GAAP 1 The company's results third quarter 2017 included charge 52 million related business optimization initiatives This included charge 31 million related restructuring activities 21 million costs implement business optimization programs primarily included external consulting project employee costs The 31 million restructuring charges comprised employee termination costs The company results first nine months 2017 included net charge 116 million related business optimization initiatives This included net charge 50 million related restructuring activities 58 million costs implement business optimization programs primarily included external consulting project employee costs 8 million accelerated depreciation associated facilities closed The 50 million net restructuring charges included 40 million employee termination costs 5 million contract termination costs 5 million asset impairment charges primarily related facility closures The company results third quarter 2016 included net charge 171 million related business optimization initiatives This included net charge 130 million related restructuring activities 25 million costs implement business optimization programs included external consulting employee salary related costs 11 million accelerated depreciation associated facilities closed 5 million Gambro integration costs The 130 million restructuring activities included 101 million employee termination costs 27 million intangible asset impairment charges related acquired in-process R&D 2 million exit costs The company results first nine months 2016 included net charge 325 million related business optimization initiatives This included net charge 237 million related restructuring activities 44 million costs implement business optimization programs included external consulting employee salary related costs 25 million accelerated depreciation associated facilities closed 19 million Gambro integration costs The 237 million restructuring activities included 144 million employee termination costs 54 million costs related discontinuance VIVIA home hemodialysis development program 27 million intangible asset impairment charges related acquired in-process R&D 12 million exit costs 2 The company results third quarter first nine months 2017 included net charge 21 million 17 million respectively related SIGMA SPECTRUM infusion pump inspection remediation activities partially offset benefit related adjustment historical product reserves The company results first nine months 2016 included benefit 12 million related adjustment SIGMA SPECTRUM infusion pump reserves 3 The company results first nine months 2016 included 51 million impairment primarily related developed technology 4 The company's results 2017 2016 included costs incurred related Baxalta separation totaling 2 million 10 million respectively third quarter 17 million 46 million respectively first nine months 5 The company's results first nine months 2017 included benefit 12 million related adjustment company's historical rebates discounts reserve 6 The company results third quarter 2016 included net debt extinguishment loss 48 million primarily related certain debt redemptions The company results 2016 included net debt extinguishment loss totaling 149 million related March 2016 debt-for-equity exchange certain company indebtedness certain debt redemptions See Note 8 within Item 1 additional details 7 The company results first nine months 2016 included net realized gains 4.4 billion related debt-for-equity exchanges Baxalta Retained Shares certain company indebtedness equity-for-equity exchange pension contribution described Refer Note 8 within Item 1 additional details 8 The company results third quarter first nine months 2017 include acquisition integration costs 15 million 20 million respectively related company acquisition Claris Injectables Limited Claris 9 The company results 2017 included charge 33 million related deconsolidation Venezuelan operations 10 The company results 2017 included charge 21 million related impact Hurricane Maria company operations Puerto Rico The costs primarily include inventory fixed asset impairments well idle facility costs 27 NET SALES Three months ended September 30 Percent change millions 2017 2016 At actual currency rates At constant currency rates U.S Cyclophosphamide Claris Strategic Product Exits Renal 1,010 977 3 3 0 0 3 Hospital Products 1,697 1,581 7 7 0 2 1 Total net sales 2,707 2,558 6 6 0 1 1 Three months ended September 30 Percent change millions 2017 2016 At actual currency rates At constant currency rates U.S Cyclophosphamide Claris Strategic Product Exits International 1,559 1,491 5 4 0 1 3 United States 1,148 1,067 8 8 0 1 0 Total net sales 2,707 2,558 6 6 0 1 1 Nine months ended September 30 Percent change millions 2017 2016 At actual currency rates At constant currency rates U.S Cyclophosphamide Claris Strategic Product Exits Renal 2,874 2,840 1 2 0 0 2 Hospital Products 4,913 4,678 5 5 0 0 1 Total net sales 7,787 7,518 4 4 0 0 1 Nine months ended September 30 Percent change millions 2017 2016 At actual currency rates At constant currency rates U.S Cyclophosphamide Claris Strategic Product Exits International 4,405 4,376 1 2 0 0 2 United States 3,382 3,142 8 8 1 1 0 Total net sales 7,787 7,518 4 4 0 0 1 Foreign currency impact consolidated net sales third quarter first nine months 2017 compared prior periods The comparisons presented constant currency rates reflect comparative local currency sales prior period foreign exchange rates This measure provides information change net sales assuming foreign currency exchange rates changed prior current period The company believes non-GAAP measure change net sales constant currency rates used conjunction GAAP measure change net sales actual currency rates may provide complete understanding company operations facilitate fuller analysis company results operations particularly evaluating performance one period another During 2016 company made strategic decision exit select products certain markets including Venezuela India Turkey Overall items negative impact company net sales growth rate 1 percentage point third quarter first nine months 2017 respectively The company also presenting impact generic competition U.S cyclophosphamide enhance comparability periods better identify operating trends On July 27 2017 Baxter completed acquisition Claris wholly owned subsidiary Claris Lifesciences Limited total cash consideration 629 million net cash acquired In three nine months ended September 30 2017 consolidated Baxter results include 27 million net sales related Claris acquisition 28 In September 2017 company three Puerto Rico manufacturing sites sustained minimal structural damage impact Hurricane Maria limited production activities resumed soon thereafter Given temporary disruptions company manufacturing facilities result storm company expects net sales fourth quarter 2017 negatively impacted approximately 70 million The company expect material impact net sales 2018 thereafter Franchise Net Sales Reporting The Renal segment includes sales company peritoneal dialysis PD hemodialysis HD continuous renal replacement therapies CRRT additional dialysis services The Hospital Products segment includes four commercial franchises Fluid Systems Integrated Pharmacy Solutions Surgical Care Other Fluid Systems includes sales company intravenous IV therapies infusion pumps IV administration sets Integrated Pharmacy Solutions includes sales company premixed oncology drug platforms nutrition products pharmaceutical reconstitution devices pharmacy compounding services Surgical Care includes sales company inhaled anesthesia products critical care products well biological products medical devices used surgical procedures hemostasis tissue sealing adhesion prevention Other includes sales primarily company pharmaceutical partnering business The following summary net sales commercial franchise reported constant currency basis along impact significant non-operational items Three months ended September 30 Percent change millions 2017 2016 At actual currency rates At constant currency rates U.S Cyclo phosphamide Claris Strategic Product Exits Total Renal net sales 1,010 977 3 3 0 0 3 Fluid Systems 610 576 6 6 0 0 1 Integrated Pharmacy Solutions 627 563 11 11 2 5 0 Surgical Care 338 320 6 5 0 0 1 Other 122 122 2 0 0 0 Total Hospital Products net sales 1,697 1,581 7 7 0 2 1 Nine months ended September 30 Percent change millions 2017 2016 At actual currency rates At constant currency rates U.S Cyclo phosphamide Claris Strategic Product Exits Total Renal net sales 2,874 2,840 1 2 0 0 2 Fluid Systems 1,802 1,686 7 7 0 0 2 Integrated Pharmacy Solutions 1,747 1,682 4 5 1 1 0 Surgical Care 1,024 972 5 6 0 0 0 Other 340 338 1 1 0 0 0 Total Hospital Products net sales 4,913 4,678 5 5 0 0 1 29 Net sales Renal segment third quarter first nine months 2017 increased 3 1 respectively Excluding impact foreign currency sales increased 3 2 third quarter first nine months 2017 respectively driven continued growth PD patients adoption company new Automated Peritoneal Dialysis Cyclers APD AMIA U.S HomeChoice CLARIA international markets Increased sales globally company CRRT products also contributed growth third quarter first nine months 2017 Sales growth first nine months 2017 partially offset lower sales HD products internationally driven reduced volumes increased pricing pressures Certain international strategic market exits negatively impacted Renal segment net sales 3 2 third quarter first nine months 2017 respectively expected negatively impact full year Renal segment net sales approximately 50 million compared 2016 Net sales Hospital Products segment increased 7 5 respectively third quarter first nine months 2017 compared prior period reported basis constant currency basis Certain international strategic market exits negatively impacted Hospital Products segment net sales 1 third quarter first nine months 2017 expected negatively impact full year 2017 net sales approximately 50 million compared 2016 The company acquisition Claris contributed 27 million net sales third quarter first nine months 2017 The principal drivers impacting net sales following In Fluid Systems franchise sales increased 6 third quarter 7 first nine months 2017 constant currency basis driven select pricing improved volumes U.S IV solutions This increase also positively impacted increased sales company IV access administrative sets reflecting on-going pull company growing SPECTRUM infusion pump base In Integrated Pharmacy Solutions franchise sales increased 11 third quarter 5 first nine months 2017 constant currency basis driven improved volumes company nutritional therapies increased sales pre-mixed injectable drugs result recent product launches acquisition Claris one-time benefit early contract settlement These increases offset decreased U.S sales cyclophosphamide generic oncology drug due entry competitors market U.S sales cyclophosphamide declined 163 million first nine months 2016 143 million first nine months 2017 The company expects U.S sales cyclophosphamide continue decline due entrance additional competitors In Surgical Care franchise sales increased 5 third quarter 6 first nine months 2017 constant currency basis driven improved volumes pricing U.S company portfolio anesthetic critical care products positive demand inhaled anesthetics internationally The increase principally due pricing BREVIBLOC fast-acting IV beta blocker third quarter first nine months 2017 well volume Transderm Scop first nine months The increased Transderm Scop volume result temporary supply disruption first half year related alternative product In Other franchise sales decreased 2 third quarter increased 1 first nine months 2017 constant currency basis driven unfavorable volumes third quarter favorable volumes first nine months 2017 products manufactured Baxter behalf pharmaceutical partners In addition revenues related company manufacturing supply agreement Baxalta lower third quarter first nine months 2017 compared prior year Gross Margin Expense Ratios Three months ended Nine months ended September 30 September 30 percentage net sales 2017 2016 Change 2017 2016 Change Gross margin 41.7 41.9 0.2 pts 42.4 40.0 2.4 pts Marketing administrative expenses 25.3 28.4 3.1 pts 24.3 27.6 3.3 pts Gross Margin The special items identified unfavorable impact approximately 3.5 2.5 percentage points gross margin ratio third quarter first nine months 2017 respectively The unfavorable impact 3.0 3.7 percentage points third quarter first nine months 2016 respectively Refer Special Items caption additional detail 30 Excluding impact special items gross margin ratio increased due select price increases favorable manufacturing performance benefit company business transformation initiatives aimed simplifying portfolio drive efficiency reduce costs Marketing Administrative Expenses The special items identified unfavorable impact approximately 1.9 1.2 percentage points marketing administrative expense ratio third quarter first nine months 2017 respectively The unfavorable impact 4.5 2.4 percentage points third quarter first nine months 2016 Refer Special Items caption additional detail Excluding impact special items marketing administrative expenses ratio third quarter first nine months 2017 declined due actions taken company rebase cost structure focus expense management These savings partially offset decreased benefits marketing administrative expenses ratio lower transition service income agreement Baxalta services continues wind Research Development Three months ended September 30 Percent Nine months ended September 30 Percent millions 2017 2016 change 2017 2016 change Research development expenses 151 159 5 435 490 11 As percentage net sales 5.6 6.2 5.6 6.5 The special items identified unfavorable impact approximately 1.2 1.0 percentage points third quarter first nine months 2016 Refer Special Items caption additional detail Excluding impact special items research development expenses ratio increased third quarter first nine months 2017 result company increased investment new product development Business Optimization Items Beginning second half 2015 company initiated actions transform costs structure enhance operational efficiency These efforts include restructuring organization optimizing manufacturing footprint R&D operations supply chain network employing disciplined cost management centralizing streamlining certain support functions Through September 30 2017 company incurred pretax costs 526 million related actions The costs consisted primarily employee termination costs implementation costs accelerated depreciation The company expects incur additional pretax costs approximately 285 million capital expenditures 90 million related initiatives end 2018 These costs primarily include employee termination costs implementation costs accelerated depreciation The company expects approximately 5 percent remaining charges non-cash These actions aggregate expected provide future annual pretax savings approximately 950 million The savings actions impact cost sales marketing administrative expenses research development expenses Approximately 85 percent expected annual pretax savings expected realized end 2018 remainder end 2020 Refer Note 7 Item 1 additional information regarding company business optimization initiatives Net Interest Expense Net interest expense 14 million 41 million third quarter first nine months 2017 respectively 14 million 53 million third quarter first nine months 2016 respectively The decrease first nine months 2017 primarily driven lower outstanding debt result first quarter 2016 debt-for-equity exchanges extinguished 3.65 billion debt well reduced coupon rates related third quarter 2016 debt issuance partially offset lower interest capitalized assets construction See Note 8 within Item 1 additional details debt extinguishments Other Income Expense Net Other income expense net income 12 million expense 10 million third quarter first nine months 2017 respectively expense 44 million income 4.3 billion third quarter first nine months 2016 respectively Special items periods presented included 4.4 billion net realized gain Baxalta Retained Shares transactions 31 first nine months 2016 101 million debt extinguishment loss first quarter 2016 48 million debt extinguishment loss third quarter 2016 33 million loss deconsolidation company Venezuelan subsidiary second quarter 2017 Excluding impact special items income expense net higher income third quarter 2017 lower income first nine months 2017 compared 2016 Higher income third quarter 2017 result foreign currency fluctuations principally related intercompany receivables payables monetary assets denominated foreign currency Lower income first nine months 2017 attributable absence dividends Retained Shares received Baxalta 2016 recognized investment impairment losses 2017 Segment EBITDA The company uses income continuing operations net interest expense income tax expense depreciation amortization expense Segment EBITDA segment basis make resource allocation decisions assess ongoing performance company business segments Refer Note 14 within Item 1 summary financial results segment The following summary significant factors impacting segments financial results Renal Segment EBITDA 226 million 649 million third quarter first nine months 2017 respectively 214 million 494 million third quarter first nine months 2016 respectively The increase 2017 driven lower research development costs company realigned allocations research development costs based project spend attributable segments higher gross margins due product mix lower marketing administrative expenses Renal segment benefited company business optimization programs continued focus reducing discretionary spending This growth partially offset unfavorable foreign currency Hospital Products Segment EBITDA 653 million 1.821 billion third quarter first nine months 2017 respectively 588 million 1.673 billion third quarter first nine months 2016 respectively This increase driven higher net sales lower marketing administrative expenses cost savings realized company business optimization programs continued focus reducing discretionary spending This growth partially offset higher research development costs company realigned allocations research development costs based project spend attributable segments unfavorable foreign currency Corporate Certain income expense amounts allocated segment These amounts detailed table Note 14 within Item 1 primarily include net interest expense foreign exchange fluctuations principally relating intercompany receivables payables loans denominated foreign currency majority foreign currency hedging activities corporate headquarters costs stock compensation expense non-strategic investments related income expense certain employee benefit plan costs well certain nonrecurring gains losses charges business optimization integration separation-related costs asset impairments Income Taxes The company effective income tax rate continuing operations 14.5 0.8 third quarter 15.0 1.1 first nine months 2017 2016 respectively The company effective income tax rate differs U.S federal statutory rate year due certain operations subject tax incentives state local taxes foreign taxes different U.S federal statutory rate In addition effective tax rate impacted period discrete factors events The effective income tax rate continuing operations three months ended September 30 2017 increased three months ended September 30 2016 due inclusion 2016 restructuring charges incurred higher tax rate jurisdictions well favorable impact discrete items including partial settlement on-going income tax matter related company Turkish operations settlement transfer pricing audit related company Italian operations Windfall benefits realized stock option exercises vesting RSUs PSUs associated company stock compensation programs partially offset increase prior period benefits reflected tax benefit result company adoption ASU 2016-09 2017 The effective income tax rate continuing operations increased nine months ended September 30 2017 due items noted well absence current year tax-free net realized gains associated Baxalta Retained Share 32 transactions included debt-for-equity exchanges contribution Baxalta Retained Shares company U.S pension plan exchange Baxalta Retained Shares shares company well benefits attributable closing IRS German income tax audit reflected nine months ended September 30 2016 The effective income tax rate continuing operations nine months ended September 30 2017 favorably impacted approximately 5.2 percentage points due tax windfall benefits realized stock option exercises vesting RSUs PSUs associated company stock compensation programs Income Continuing Operations Earnings per Diluted Share Income continuing operations 248 million 127 million three months ended September 30 2017 2016 respectively 785 million 4.7 billion nine months ended September 30 2017 2016 respectively Income continuing operations per diluted share 0.45 0.23 three months ended September 30 2017 2016 respectively 1.42 8.56 nine months ended September 30 2017 2016 respectively The significant factors events contributing changes discussed Income loss Discontinued Operations Discontinued operations insignificant periods presented Refer Note 2 within Item 1 additional information regarding separation Baxalta LIQUIDITY AND CAPITAL RESOURCES The following table summary statement cash flow nine month periods ended September 30 2017 2016 Nine months ended September 30 millions 2017 2016 Cash flows operations continuing operations 1,343 938 Cash flows investing activities continuing operations 1,088 549 Cash flows financing activities 391 44 Cash Flows Operations Continuing Operations Operating cash flows continuing operations increased first nine months 2017 compared prior year period The increase driven factors discussed Net Income Net income adjusted certain non-cash items depreciation amortization net periodic pension benefit OPEB costs stock compensation deferred income taxes items increased nine months ended September 30 2017 compared 2016 Additionally non-cash items nine months ended September 30 2016 included net realized gains 4.4 billion related debt-for-equity exchanges Baxalta Retained Shares certain company indebtedness equity-for-equity exchange Accounts Receivable Cash inflows accounts receivable 32 million first nine months 2017 compared inflow 22 million prior year Days sales outstanding current year comparable prior year 33 Inventories Cash outflows relating inventories decreased 2017 compared prior-year period The following summary inventories September 30 2017 December 31 2016 well annualized inventory turns first nine months 2017 2016 segment Inventories Annualized inventory turns Nine September 30 December 31 months ended September 30 millions except inventory turn data 2017 2016 2017 2016 Renal 635 544 3.77 3.58 Hospital Products 915 885 3.97 3.61 Other 1 n/a n/a Total company 1,550 1,430 3.89 3.60 The increase inventories driven primarily timing purchases longer sourcing lead times certain products within Renal segment portfolio coupled acquisition Claris Hospital Products segment Other The changes accounts payable accrued liabilities 36 million outflow first nine months 2017 compared 326 million outflow first nine months 2016 The changes primarily driven first quarter 2016 non-recurring 303 million tax settlement payment partially settle U.S Federal income tax audit well timing supplier payments Payments related execution company business optimization initiatives increased 98 million first nine months 2016 114 million first nine months 2017 The company made payments 21 million first nine months 2016 related execution COLLEAGUE infusion pump SIGMA SPECTRUM infusion pump recalls Refer Note 7 within Item 1 information regarding company business optimization initiatives Changes balance sheet items include outflow 93 million inflow 121 million first nine months 2017 2016 respectively primarily driven collection tax receivable second quarter 2016 Cash Flows Investing Activities Continuing Operations Capital Expenditures Capital expenditures 410 million 519 million first nine months 2017 2016 respectively The company capital expenditures 2017 driven targeted investments projects support production PD IV solutions Acquisitions Investments Cash outflows relating acquisitions investments 680 million first nine months 2017 primarily driven 629 million acquisition Claris acquisition rights Clindamycin Saline Clindamycin Dextrose Celerity acquisition Wound Care Technologies Inc Cash outflows relating acquisitions investments 47 million first nine months 2016 driven primarily acquisition rights Vancomycin Celerity Divestitures Other Investing Activities Cash inflows divestitures investing activities 2017 2016 significant Cash Flows Financing Activities Debt Issuances Net Payments Obligations Net cash inflows related debt financing obligations totaled 633 million first nine months 2017 primarily related issuance 600 million senior notes fixed coupon rate 1.30 due May 2025 Net cash outflows related debt financing obligations totaled 58 million first nine months 2016 primarily related 190 million repayment company 0.95 senior unsecured notes matured June 2016 130 million repayment company 5.9 senior unsecured notes matured September 2016 redemption approximately 1 billion 34 aggregate principal amount senior notes September 2016 well short-term obligations The company also 300 million net repayments related commercial paper program This partially offset issuances debt totaling 1.6 billion senior notes August 2016 See Note 8 within Item 1 additional details regarding debt transactions first nine months 2016 Other Financing Activities Cash dividend payments totaled 228 million 197 million first nine months 2017 2016 respectively The increase cash dividend payments primarily due increase quarterly dividend rate 0.115 0.13 per share quarterly dividends declared May 2016 May 2017 In addition company increased quarterly dividend rate 0.13 0.16 per share quarterly dividends declared beginning May 2017 Proceeds stock issued employee benefit plans increased 251 million first nine months 2016 298 million first nine months 2017 primarily due increased option exercises first nine months 2017 As authorized Board Directors company repurchases stock depending upon company cash flows net debt level market conditions In July 2012 Board Directors authorized repurchase 2.0 billion company common stock The Board Directors increased authority additional 1.5 billion November 2016 The company paid 275 million cash repurchase approximately 4.7 million shares pursuant authority first nine months 2017 1.4 billion remaining available authorization September 30 2017 In first nine months 2016 company paid 45 million cash repurchase shares In first nine months 2016 company executed equity-for-equity exchange Baxalta Retained Shares 11.5 million outstanding Baxter shares Credit Facilities Access Capital Credit Ratings Credit Facilities As September 30 2017 company U.S dollar-denominated revolving credit facility Euro-denominated senior revolving credit facility maximum capacity 1.5 billion approximately 200 million respectively As September 30 2017 company compliance financial covenants agreements The non-performance financial institution supporting either credit facilities would reduce maximum capacity facilities institution respective commitment Access Capital The company intends fund short-term long-term obligations mature cash hand future cash flows operations issuing additional debt The company 3.5 billion cash equivalents September 30 2017 adequate cash available meet operating requirements jurisdiction company operates The company invests excess cash certificates deposit money market funds diversifies concentration cash among different financial institutions The company ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company products solvency customers suppliers deterioration company key financial ratios credit ratings significantly unfavorable changes conditions However company believes sufficient financial flexibility issue debt enter financing arrangements attract long-term capital acceptable terms support company growth objectives The company continues business foreign governments certain countries including Greece Spain Portugal Italy experienced deterioration credit economic conditions As September 30 2017 company net accounts receivable public sector Greece Spain Portugal Italy totaled 151 million While economic conditions significantly impacted company ability collect receivables global economic conditions liquidity issues certain countries resulted may continue result delays collection receivables credit losses 35 Credit Ratings The company credit ratings September 30 2017 follows Standard Poor Fitch Moody Ratings Senior debt A BBB Baa2 Short-term debt A2 F2 P2 Outlook Stable Stable Stable CRITICAL ACCOUNTING POLICIES The preparation financial statements accordance GAAP requires management make estimates judgments affect reported amounts assets liabilities revenues expenses A summary company significant accounting policies included Note 1 company consolidated financial statements 2016 Annual Report Certain company accounting policies considered critical policies important depiction company financial statements require significant difficult complex judgments often employing use estimates effects matters inherently uncertain Such policies summarized Management Discussion Analysis Financial Condition Results Operations section 2016 Annual Report There significant changes company application critical accounting policies first nine months 2017 LEGAL CONTINGENCIES Refer Note 13 within Item 1 discussion company legal contingencies Upon resolution uncertainties company may incur charges excess presently established liabilities While liability company connection certain claims cannot estimated certainty although resolution reporting period one matters could significant impact company results operations cash flows period outcome legal proceedings expected material adverse effect company consolidated financial position While company believes valid defenses matters litigation inherently uncertain excessive verdicts occur company may future incur material judgments enter material settlements claims CERTAIN REGULATORY MATTERS The U.S Food Drug Administration FDA commenced inspection Claris facilities Ahmedabad India July 27 2017 immediately prior closing Claris acquisition FDA completed inspection August 4 2017 time FDA issued related Form-483 Claris 483 The Claris 483 includes number observations across variety areas The company submitted timely response Claris 483 process implementing corrective preventive actions included product recalls financially immaterial company address FDA observations items identified connection integrating Claris company quality systems In January 2014 company received Warning Letter FDA primarily directed quality systems company Round Lake Illinois facility particularly facility capacity specification developer certain company medical devices This Warning Letter lifted February 2017 The company received Warning Letter December 2013 included observations related company ambulatory infuser business Irvine California previously subject agency action This Warning Letter lifted May 2017 In June 2013 company received Warning Letter FDA regarding operations processes North Cove North Carolina Jayuya Puerto Rico facilities The company attended Regulatory Meetings FDA November 2015 concerning Jayuya facility The company also requested participated Regulatory Meeting regarding facilities July 2017 The Warning Letter addresses observations related Current Good Manufacturing Practice violations two facilities In June 2010 company received Warning Letter FDA connection inspection McGaw Park Illinois facility previously supported Renal franchise The company Round Lake facility provides related capacity Renal franchise The Warning Letter pertains processes company analyzes addresses product complaints corrective preventative action reports relevant information FDA This Warning Letter lifted February 2017 36 On October 9 2014 company Regulatory Meeting FDA discuss Warning Letters described At meeting company agreed work closely FDA provide regular updates progress meet requirements resolve matters identified Warning Letters described Please see Item 1A 2016 Annual Report Item 1 Part II quarterly report additional discussion regulatory matters may impact company FORWARD-LOOKING INFORMATION This quarterly report includes forward-looking statements Use words may would could believes estimates projects potential expects plans seeks intends evaluates pursues anticipates continues designs impacts affects forecasts target outlook initiative objective designed priorities goal negative words similar expressions intended identify forward-looking statements represent current judgment possible future events These forward-looking statements may include statements respect accounting estimates assumptions litigation-related matters including outcomes future regulatory filings company R&D pipeline strategic objectives credit exposure foreign governments potential developments respect credit ratings investment foreign earnings estimates liabilities including related uncertain tax positions contingent payments future pension plan contributions costs discount rates rates return company exposure financial market volatility foreign currency interest rate risks potential tax liability associated separation company biopharmaceuticals medical products businesses including 2016 disposition company Retained Shares Baxalta impact competition future sales growth business development activities including recent acquisition Claris Injectables July 2017 business optimization initiatives cost saving initiatives future capital R&D expenditures future debt issuances manufacturing expansion sufficiency company facilities financial flexibility adequacy credit facilities tax provisions reserves effective tax rate statements relate historical facts These forward-looking statements based certain assumptions analyses made light company experience perception historical trends current conditions expected future developments well factors company believes appropriate circumstances While statements represent company current judgment future may hold company believes judgments reasonable statements guarantees events financial results Whether actual future results developments conform expectations predictions subject number risks uncertainties including following factors many beyond control failure achieve long-term financial improvement goals demand market acceptance risks competitive pressures related new existing products impact products quality patient safety concerns product development risks including satisfactory clinical performance ability manufacture appropriate scale general unpredictability associated product development cycle product quality patient safety issues leading product recalls withdrawals launch delays warning letters import bans sanctions seizures litigation declining sales future actions failures act delays acting FDA European Medicines Agency regulatory body government authority including U.S Department Justice New York Attorney General could delay limit suspend product development manufacturing sale result seizures recalls injunctions monetary sanctions criminal civil liabilities failures respect company quality compliance ethics programs future actions third parties including third-party payers healthcare reform similar measures implemented modified repealed United States globally impact ongoing U.S healthcare reform similar actions undertaken foreign governments respect pricing reimbursement taxation rebate policies additional legislation regulation governmental pressures United States globally may affect pricing reimbursement taxation rebate policies government agencies private payers elements company business impact competitive products pricing including generic competition drug reimportation disruptive technologies 37 global regulatory trade tax policies company ability identify business development growth opportunities successfully execute business development strategies company ability finance develop new products enhancements commercially acceptable terms availability pricing acceptable raw materials component supply inability create additional production capacity timely manner occurrence manufacturing supply difficulties including result natural disaster otherwise impact future tax liability respect separation distribution including respect disposition Retained Shares failure Baxalta Shire satisfy obligation separation agreements including tax matters agreement company letter agreement Shire Baxalta ability protect enforce company owned in-licensed patent proprietary rights including trademarks copyrights trade secrets know-how patents third parties preventing restricting company manufacture sale use affected products technology impact global economic conditions company customers suppliers including foreign governments certain countries company operates fluctuations foreign exchange interest rates changes law concerning taxation income including income earned outside United States may part comprehensive tax reform actions tax authorities connection ongoing tax audits breaches failures company information technology systems loss key employees inability identify recruit new employees outcome pending future litigation adequacy company cash flows operations meet ongoing cash obligations fund investment program factors identified elsewhere report filings Securities Exchange Commission including factors described Item 1A company Annual Report Form 10-K year ended December 31 2016 available company website Actual results may differ materially projected forward-looking statements The company undertake update forward-looking statements 38 Item 3 Quantitative Qualitative